Endocrine Abstracts

Introduction: SGLT2 inhibitors offer a novel approach to improve glycaemic control in patients with type 2 diabetes through inhibition of renal glucose reabsorption. Phase 3 clinical trials demonstrated consistent glucose lowering effects and weight loss. The objective of our audit was to assess the early effects of treatment with dapagliflozin 10 mg in our clinic population.Methods: We performed a retrospective audit of clinical parameters in patients (...